Roche Holding AG EPS - Earnings per Share 2010-2024 | RHHBY

Roche Holding AG annual and quarterly earnings per share history from 2010 to 2024. Earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
  • Roche Holding AG EPS for the quarter ending December 31, 2024 was $0.00, a 0% increase year-over-year.
  • Roche Holding AG EPS for the twelve months ending December 31, 2024 was $0.00, a 0% increase year-over-year.
  • Roche Holding AG 2024 annual EPS was $1.46, a 26.54% decline from 2023.
  • Roche Holding AG 2023 annual EPS was $1.99, a 0.99% decline from 2022.
  • Roche Holding AG 2022 annual EPS was $2.01, a 9.12% decline from 2021.
Roche Holding AG Annual EPS
2024 $1.46
2023 $1.99
2022 $2.01
2021 $2.22
2020 $2.20
2019 $1.97
2018 $1.56
2017 $1.28
2016 $1.41
2015 $1.34
2014 $1.48
2013 $0.87
2012 $0.75
2011 $1.50
2010 $1.35
2009 $1.09
Roche Holding AG Quarterly EPS
2024-12-31 $0.00
2024-06-30 $0.00
2023-12-31 $0.00
2023-06-30 $0.00
2022-12-31 $0.00
2022-06-30 $0.00
2021-12-31 $0.00
2021-06-30 $0.00
2020-12-31 $0.00
2020-06-30 $0.00
2019-12-31 $0.00
2019-06-30 $0.00
2018-12-31 $0.00
2018-06-30 $0.00
2017-12-31 $0.00
2017-06-30 $0.00
2016-12-31 $0.00
2016-06-30 $0.00
2015-12-31 $0.00
2015-06-30 $0.00
2014-12-31 $0.00
2014-06-30 $0.00
2013-12-31 $0.00
2013-06-30 $0.00
2012-12-31 $0.00
2012-06-30 $0.00
2011-12-31 $0.00
2011-06-30 $0.00
2010-12-31 $0.00
2010-06-30 $0.00
2009-12-31 $0.00
2009-06-30 $0.00
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $244.721B $68.726B
Basel, Switzerland-based Roche Holding Ltd. is a leading health care company focused on developing and commercializing innovative diagnostic and therapeutic products and services, which enable early detection and prevention of diseases as well as their treatment and monitoring. The company conducts its operations through two segments ' Pharmaceuticals and Diagnostics.Pharmaceuticals: Key focus areas in this segment include Oncology, Virology, Inflammation, Metabolism and Neuroscience. Diagnostics: The Diagnostics Division operates in four segments ' Roche Professional Diagnostics, Roche Diabetes Care, Roche Molecular Diagnostics, and Roche Tissue Diagnostics. In September 2014, Roche acquired InterMune for $8.3 billion and added Esbriet to its portfolio. During the first quarter of 2018, Roche acquired Flatiron Health and Ignyta, Inc.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $696.178B 53.38
Johnson & Johnson (JNJ) United States $371.065B 15.35
AbbVie (ABBV) United States $326.553B 17.97
Novartis AG (NVS) Switzerland $229.620B 13.11
Merck (MRK) United States $190.763B 9.75
Pfizer (PFE) United States $126.670B 6.94
Sanofi (SNY) France $126.061B 12.05
Bayer (BAYRY) Germany $26.722B 4.96
Innoviva (INVA) United States $1.163B 12.21
Novo Nordisk (NVO) Denmark $0.000B 19.46